Lured by growth prospects and confident in their own quality, global pharmaceutical manufacturers are acquiring firms that have struggled on quality in the low-margin, technically difficult generic injectables market segment.
Key
Pharma Pursues Generic Injectables Quality Turnaround Opportunities
Pfizer’s plan to acquire Hospira is part of a turnaround trend in which Big Pharma hopes its quality will rub off on the troubled generics injectables sector. The question is: Will it work?